 "AstraZeneca Pharma falls on receiving termination notice for Meronem")
AstraZeneca Pharma India has dipped 8% to Rs 1,050 on the BSE in intra-day trade after the company said it has received notice from AstraZeneca UK for termination of distribution arrangements for Meronem in India.
“This is as result of a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc, of its late-stage small molecule antibiotics business,” AstraZeneca Pharma India said in a statement.
Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients.
The current distribution arrangements for Meronem in India will terminate in six months from August 24, 2016.
Meronem is currently one of the company’s principle products. It generated 18% of the total turnover of the company in the financial year ended March 31, 2016, it added.
The global transaction between AstraZeneca PLC and Pfizer Inc. is expected to close in the fourth quarter of the year 2016, subject to customary closing conditions.
At 10:16 am, the stock was down 6.4% to Rs 1,067, as compared to 0.27% rise in the S&P BSE Sensex. A combined 57,507 shares changed hands on the counter on the NSE and BSE.
“This is as result of a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc, of its late-stage small molecule antibiotics business,” AstraZeneca Pharma India said in a statement.
Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients.
The current distribution arrangements for Meronem in India will terminate in six months from August 24, 2016.
Meronem is currently one of the company’s principle products. It generated 18% of the total turnover of the company in the financial year ended March 31, 2016, it added.
The global transaction between AstraZeneca PLC and Pfizer Inc. is expected to close in the fourth quarter of the year 2016, subject to customary closing conditions.
At 10:16 am, the stock was down 6.4% to Rs 1,067, as compared to 0.27% rise in the S&P BSE Sensex. A combined 57,507 shares changed hands on the counter on the NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%